Abstract
The following chapter will discuss the history and clinical utility of several different composite risk models. Composite risk models are used to combine the various known risk factors and translate them into a more easily interpretable risk value. The Framingham Risk Algorithm is among the oldest and most widely used risk scores for cardiovascular disease, and over the years, new cardiovascular disease risk algorithms, such as the Reynolds Risk Score and the Pooled Cohort Equations, have been developed. However, the applicability of these scores to ethnically and socioeconomically diverse populations has been questioned. As well, several lifetime cardiovascular disease models have been developed, but the clinical utility of assessing lifetime cardiovascular risk is still debated. Furthermore, different health organizations have developed several criteria for the metabolic syndrome, yet the clinical utility of the metabolic syndrome is still debated. In recent years, staging systems for obesity and cardiometabolic health have been developed to guide medical treatment, though due to their novelty, there is limited research on their effectiveness. However, for a given risk score, there are still individual differences in actual risk score, termed residual risk. This means that even if a patient achieves target levels of metabolic risk factors, some may still experience a cardiac event even if their predicted risk is low. This residual cardiovascular risk that is not accounted for by the risk models is true for all algorithms but can be reduced by adopting a healthy lifestyle or improving other important factors not accounted for by the algorithm. Finally, risk assessment is only valuable if the patient understands what that risk means, and therefore optimal risk communication between health professional and patient is vital for improving patient care. This review will describe the development and clinical utility of the Framingham Risk Score, the Reynolds Risk Score, the Pooled Cohort Equations, lifetime risk scores, the metabolic syndrome, the Edmonton Obesity Staging System, and the Cardiometabolic Disease Staging System. Residual cardiovascular risk and patient communication will also be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACC:
-
American College of Cardiology
- AHA:
-
American Heart Association
- ARIC:
-
Atherosclerosis risk in communities
- AS:
-
Atherosclerotic
- BMI:
-
Body mass index
- CARDIA:
-
Cardiovascular Health Study, Coronary Artery Risk Development in Young Adults
- CHD:
-
Coronary heart disease
- CMDS:
-
Cardiometabolic disease staging system
- CVD:
-
Cardiovascular disease
- DASH:
-
Dietary approaches to stop hypertension
- EGIR:
-
European Group for the Study of Insulin Resistance
- EOSS:
-
Edmonton Obesity Staging System
- GLP-1:
-
Glucagon-peptide 1
- HDL-C:
-
High-density lipoprotein cholesterol
- HIV:
-
Human immunodeficiency virus
- hs-CRP:
-
High-sensitivity C-reactive protein
- IDF:
-
International Diabetes Federation
- IGT:
-
Impaired glucose tolerance
- LDL-C:
-
Low-density lipoprotein cholesterol
- MetS:
-
Metabolic syndrome
- MI:
-
Myocardial infarction
- NCEP ATP III:
-
National Cholesterol Education Program Adult Treatment Program III
- SBP:
-
Systolic blood pressure
- T2D:
-
Type-2 diabetes
- TC:
-
Total cholesterol
- WC:
-
Waist circumference
- WHO:
-
World Health Organization
References
Blaum CS, Xue QL, Michelon E, Semba RD, Fried LP. The association between obesity and the frailty syndrome in older women: the Women’s Health and Aging Studies. J Am Geriatr Soc. 2005;53(6):927–34.
D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.
Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59.
Fruchart J-C, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319–35.
Fruchart J-C, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.
Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Heart Study. Am J Public Health Nations Health. 1951;41:279–86.
Bitton A, Gaziano T. The Framingham Heart Study’s impact on global risk assessment. Prog Cardiovasc Dis. 2010;53(1):68–78.
Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chron Dis. 1967;20:511–24.
Bitton A, Gaziano T. The Framingham Heart Study’s impact on global risk assessment. Prog Cardiovasc Dis. 2010;53(1):68–78.
Kannel B, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51.
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–62.
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.
Expert Panel on Detection, Evaluation and T of HBC in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.
Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752–9.
Tzoulaki I, Seretis A, Ntzani EE, Ioannidis JPA. Mapping the expanded often inappropriate use of the Framingham Risk Score in the medical literature. J Clin Epidemiol. 2014;67:571–7.
Empana J. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Hear J. 2003;24:1903–11.
Tillin T, Hughes AD, Whincup P, et al. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE–Southall And Brent REvisited). Heart. 2014;100:60–7.
Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GCM. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005;55:838–45.
D’Agostino RB, Grundy SM, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores. JAMA. 2001;286(2):180–7.
Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.
Sposito AC, Alvarenga BF, Alexandre AS, et al. Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. Atherosclerosis. 2011;214(1):148–50.
Pen A, Yam Y, Chen L, Dennie C, McPherson R, Chow BJW. Discordance between Framingham Risk Score and atherosclerotic plaque burden. Eur Heart J. 2013;34:1075–82.
Ferket BS, van Kempen BJH, Hunink MGM, et al. Predictive value of updating Framingham risk scores with novel risk markers in the U.S. general population. PLoS ONE. 2014;9(2):e88312.
Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955–9.
Lloyd-Jones D, Nam B-J, D’Agostino R, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204–11.
Anderson TJ, Grégoire J, Hegele R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67.
Stern RH. Problems with modified Framingham Risk Score. Can J Cardiol. 2014;30:248.e3.
Ridker P, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–20.
Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243–51.
Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the Multiethnic Women’s Health Initiative. Circulation. 2012;125(14):1748–56.
Tattersall MC, Gangnon RE, Karmali KN, Keevil JG. Women up, men down: the clinical impact of replacing the Framingham Risk Score with the Reynolds Risk Score in the United States population. PLoS ONE. 2012;7(9):e44347.
Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michos ED. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014;63(25 Pt A):2789–94.
Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311(14):1406–15.
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. The Lancet. 2013;382(9907):1762–5.
Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416–23.
Lloyd-Jones D, Larson M, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. The Lancet. 1999;353:89–92.
Hippisley-cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.
Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. The Lancet. 2008;371:1547–9.
Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the CARDIA and MESA studies. Circulation. 2009;119(3):382–9.
Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8.
Berry J, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9.
Pencina MJ, D’Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation. 2009;119:3078–84.
Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2014;308(17):1795–801.
Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225–8.
Sampson U, Fazio S, Linton M. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10.
Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.
Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International. Circulation. 2009;120(16):1640–5.
Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:5395–53.
Després J-P. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38(1):52–63.
Organization WH. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. 1999.
Balkau B, Charles M. Comment on the provisional report from the WHO. Diabet Med. 1999;16:442–3.
Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice. 2005;50(3):31–3.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.
Cheung BMY, Ong KL, Man YB, Wong LYF, Lau C-P, Lam KSL. Prevalence of the metabolic syndrome in the United States National Health and Nutrition Examination Survey 1999–2002 according to different defining criteria. J Clin Hypertens. 2006;8:562–70.
Lakka H-M, Laaksonen DE, Lakka T, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–16.
McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385–90.
Marcovecchio ML, Chiarelli F. Metabolic syndrome in youth: chimera or useful concept? Curr Diab Rep. 2013;13:56–62.
Sabin M, Magnussen CG, Juonala M, Cowley M, Shield JPH. The role of pharmacotherapy in the prevention and treatment of paediatric metabolic syndrome–Implications for long-term health: part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharm Res. 2012;65:397–401.
Shahar E. Metabolic syndrome? A critical look from the viewpoints of causal diagrams and statistics. J Cardiovasc Med. 2010;11(10):772–9.
Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087–94.
Jennings CL, Lambert EV, Collins M, Levitt NS, Goedecke JH. The atypical presentation of the metabolic syndrome components in black African women: the relationship with insulin resistance and the influence of regional adipose tissue distribution. Metabolism. 2009;58:149–57.
Kuk J, Ardern C. Age and sex differences in the clustering association with mortality risk. Diabetes Care. 2010;33(11):2457–61.
Wildman RP, Muntner P, Reynolds K, Mcginn AP. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med. 2008;168(15):1617–24.
Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2005;28:2289–304.
Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. All-cause mortality associated with specific combinations of the metabolic syndrome according to recent definitions. Diabetes Care. 2007;30:2381–7.
Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27:978–83.
Ford E. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care. 2005;28(7):1769–78.
Sattar N. Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes. 2008;32:S30–S4.
Benetos A, Thomas F, Pannier B, Bean K, Jégo B, Guize L. All-cause and cardiovascular mortality using the different definitions of metabolic syndrome. Am J Cardiol. 2008;102:188–91.
Wannamethee SG, Shaper a G, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644–50.
Stern M, Williams K, Gonzalez-Villalpando C, Hunt K, Haffner S. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676–81.
Ford ES. Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S. Diabetes Care. 2005;28(7):1808–9.
Zemel M. Dietary pattern and hypertension: the DASH study. Nutr Rev. 1997;55(8):303–5.
Bhattacharyya OK, Estey E, Cheng AYY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician. 2009;55:39–43.
Ye H, Charpin-El Hamri G, Zwicky K, Christen M, Folcher M, Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A. 2013;110(1):141–6.
Simmons RK, Alberti KGMM, Gale E a M, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53(4):600–5.
Sharma a M, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33(3):289–95.
National Heart, Lung, and Blood Institute Obesity Education Initiative Expert Panel on the Identification, Evaluation and T of O and O in A. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. 1998.
Kuk J, Ardern C. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care. 2009;32(12):2297–9.
Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med. 2008;168(15):1617–24.
Kantartzis K, Machann J, Schick F, et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia. 2011;54(4):864–8.
Karelis a D, Messier V, Brochu M, Rabasa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia. 2008;51(9):1752–4.
Kuk J, Ardern C, Church T, et al. Edmonton Obesity Staging System: association with weight history and mortality risk. Appl Physiol Nutr Metab. 2011;36:570–6.
Padwal R, Pajewski N, Allison D, Sharma A. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ. 2011;183(14):1059–66.
O’Connor KG, Harman SM, Stevens TE, et al. Interrelationships of spontaneous growth hormone axis activity, body fat, and serum lipids in healthy elderly women and men. Metabolism. 1999;48(11):1424–31.
Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014;22:110–8.
Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity. 2014;22:110–8.
Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324:827–30.
Wells S, Kerr A, Eadie S, Wiltshire C, Jackson R. ‘Your Heart Forecast’: a new approach for describing and communicating cardiovascular risk? Heart. 2010;96(9):708–13.
Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ. 2003;327:741–4.
Goodyear-Smith F, Arrol B, Chan L, Jackson R, Wells S, Kenealy T. Patients prefer pictures to numbers to express cardiovascular benefit. Ann Fam Med. 2008;6:213–7.
Jackson R. Lifetime risk: does it help to decide who gets statins and when? Curr Opin Lipidol. 2014;25(4):247–53.
Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002;324:827–30.
Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ. 2003;327:741–4.
Bonner C, Jansen J, McKinn S, et al. Communicating cardiovascular disease risk: an interview study of General Practitioners’ use of absolute risk within tailored communication strategies. BMC Fam Pract. 2014;15:106.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Brown, R., Kuk, J. (2016). Composite Risk Scores. In: Mechanick, J., Kushner, R. (eds) Lifestyle Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-24687-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-24687-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-24685-7
Online ISBN: 978-3-319-24687-1
eBook Packages: MedicineMedicine (R0)